Monoclonal gammopathy of renal significance (MGRS)
MGRS · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Kidney disease caused by a nephrotoxic monoclonal immunoglobulin from a small B-cell or plasma-cell clone that does not meet criteria for myeloma or lymphoma. Despite a 'benign' haematological label, the renal lesion progresses, so the clone must be identified and treated.
Red flags
- Rapidly progressive renal failure
- Features suggesting progression to myeloma/lymphoma (anaemia, hypercalcaemia, lytic lesions)
- Nephrotic syndrome with thrombosis
- Cryoglobulinaemic vasculitis
- Recurrent disease in a kidney transplant
Assessment
Differential diagnosis
- MGRS (various lesions: MIDD, AL amyloid, proliferative GN with monoclonal deposits, light-chain Fanconi)
- Multiple myeloma / lymphoma (meets malignancy criteria)
- Primary glomerular disease unrelated to paraprotein
- Diabetic/hypertensive nephropathy
- Cryoglobulinaemic GN
- Cast nephropathy
Investigations
- Serum/urine electrophoresis with immunofixation and serum free light chains
- Urine ACR/PCR, urinalysis and renal function
- Renal biopsy with immunofluorescence, electron microscopy and staining for monoclonal deposits (key diagnostic step)
- Bone marrow biopsy and flow cytometry to characterise the clone
- Skeletal survey/imaging to exclude myeloma end-organ damage
- Complement (for proliferative GN with monoclonal deposits)
Management
- Suspect MGRS when otherwise unexplained renal disease occurs with a monoclonal protein that does not meet myeloma/lymphoma criteria
- Confirm the renal lesion and its link to the paraprotein with renal biopsy (immunofluorescence/EM showing monoclonal deposits)
- Characterise the underlying clone (plasma cell vs B-cell) with bone marrow and flow cytometry
- Exclude frank myeloma/lymphoma requiring standard oncological treatment
- Refer jointly to haematology — treatment is clone-directed, not watchful waiting
- Direct therapy at the clone: plasma-cell clones with bortezomib-based regimens, B-cell clones with rituximab-based regimens
- Consider autologous stem cell transplant in selected fit patients with amyloid/plasma-cell clones
- Provide supportive nephroprotection (RAAS blockade, BP and proteinuria control)
- Monitor haematological response (free light chains) and renal response
- Treat only after clonal control if transplantation is planned (high recurrence risk otherwise)
- Avoid nephrotoxins and manage CKD complications
- Maintain long-term joint nephrology-haematology follow-up
Drugs & doses
Bortezomib-based regimen (e.g. bortezomib-cyclophosphamide-dexamethasone) for plasma-cell clones, per haematology
Rituximab 375 mg/m2 IV weekly x4 for B-cell/lymphoplasmacytic clones
Dexamethasone as part of clone-directed therapy (protocol-dosed)
Ramipril 2.5-10 mg PO daily (nephroprotection)
Daratumumab-based regimens in selected cases per haematology
Disposition
Joint nephrology-haematology management with renal biopsy and bone marrow assessment. Clone-directed therapy; transplant only after clonal control.
Complications & pitfalls
- Progressive CKD/end-stage kidney disease
- Recurrence in transplanted kidneys without clonal control
- Progression to overt haematological malignancy
- Nephrotic complications
- Treatment toxicity
Exam pearls
- 'Benign' monoclonal gammopathy can be anything but benign for the kidney — treat the clone
- Renal biopsy linking the lesion to the monoclonal protein is essential
- Treatment targets the clone, not an arbitrary paraprotein level
- Achieve clonal control before transplantation to limit recurrence
- A multidisciplinary nephrology-haematology approach is standard
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.